Junctional epidermolysis bullosa ( JEB) is a variant of EB where ... University of Miami School of Medicine, Miami, FL. Alyssa Feiner, MD, is a Medical Student, University of Miami School of ...

Mutations in these genes, or in COL17A1, disrupt epithelial cell anchorage and cause junctional epidermolysis bullosa (EB), a genetic disorder where patients suffer from extremely fragile surface ...

This approval marks Abeona's entry into the commercial gene therapy market for dystrophic epidermolysis bullosa. The approval was granted based on results from the Phase III VIITAL study ...

dystrophic epidermolysis bullosa, junctional epidermolysis bullosa and Kindler syndrome. Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately ...

Epidermolysis Bullosa Simplex (EBS)- The most common form of EB- Usually appears in newborns- Affects the top skin layer, especially on palms and soles2. Junctional Epidermolysis Bullosa (JEB)- A ...

In December 2023, the FDA approved FILSUVEZ topical gel for the treatment of partial-thickness wounds in patients aged six months and older with Junctional or Dystrophic Epidermolysis Bullosa (JEB ...

Tayma, 9, struggles with the most severe version of Epidermolysis Bullosa, a rare, agonizing disorder that causes skin to ...

The histopathology of a biopsy taken from the periphery of the lesion demonstrated dermal-epidermal junction detachment, suggestive of epidermolysis bullosa (EB) (Figure 2). A study of the ...

Dermaliq Therapeutics and global non-profit organisation DEBRA Research have entered into a partnership aimed at advancing drug delivery into the skin for epidermolysis bullosa (EB). The non-exclusive ...

Initial programs will focus on developing innovative topical treatments and drug therapies for wound healing and itch relief, plus prophylactic therapies for people with Epidermolysis Bullosa.